American Journal of Kidney Diseases
Volume 56, Issue 5 , Pages 937-946 , November 2010

Prognostic Value of Plasma Myeloperoxidase in ESRD Patients

  • Angela Yee-Moon Wang, MD, PhD, FRCP

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    • Current affiliation: Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
    • Corresponding Author InformationAddress correspondence to Angela Yee-Moon Wang, MD, PhD, FRCP, University Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Rd, Pokfulam, Hong Kong
    • ,
  • Christopher Wai-Kei Lam, PhD, FACB

      Affiliations

    • Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    • Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau
    • ,
  • Iris Hiu-Shuen Chan, PhD

      Affiliations

    • Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    • ,
  • Mei Wang, PhD

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    • Current affiliation: Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
    • ,
  • Siu-Fai Lui, FRCP

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    • ,
  • John E. Sanderson, MD, FRCP

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong

Received 14 January 2010 ,Accepted 5 May 2010.

References 

  1. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94:437–444
  2. Savenkova M, Mueller DM, Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem. 1994;269:20394–20400
  3. Zhang R, Brennan ML, Shen Z, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002;277:46116–46122
  4. Podrez EA, Schmidt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103;:1547–1560
  5. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275:37524–37532
  6. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391–2394
  7. Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134–1139
  8. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879–891
  9. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075–2081
  10. Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, Ford DA. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation. 2003;108:3128–3133
  11. Beckman JS, Ye YZ, Anderson PG, et al. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler. 1993;375:81–88
  12. Zhang R, Brennan ML, Fu XM, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136–2142
  13. Baldus S, Heeschen C, Meinertz T, et al. CAPTURE Investigators Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–1445
  14. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001;142:336–339
  15. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med. 2004;116:429–430
  16. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2006;48:59–68
  17. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl. 2003;84:S172–S176
  18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  19. Nolph KD, Moore HL, Twardowski ZJ, et al. Cross-sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis. ASAIO J. 1992;38:M139–M142
  20. Van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1996;7:745–748
  21. Sahn DJ, De Maria A, Kisslo J, Weyman A. Committee on M-mode standardization of the American Society of Echocardiography (Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiographic measurements). Circulation. 1978;58:1072–1083
  22. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
  23. Engelstein ED, Zipes DP. Sudden cardiac death. In:  Alexander RW,  Schlant RC,  Fuster V editor. The Heart, Arteries and Veins. New York, NY: McGraw-Hill; 1998;p. 1081–1112
  24. Myerburg RJ, Castellanos A. Cardiac arrest and sudden death. In:  Braunwald E editors. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders; 1997;p. 742–779
  25. Harrell FE, Lee KL, Califf RM, et al. Regression modeling strategies for improved prognostic prediction. Stat Med. 1984;3:143–152
  26. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW. Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med. 2001;31:1163–1169
  27. Wu CC, Chen JS, Wu WM, et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant. 2005;20:1134–1139
  28. Meuwese MC, Stroes ESG, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals. J Am Coll Cardiol. 2007;50:159–165
  29. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5–12
  30. Biasucci LM, D'Onofrio G, Liuzzo G, et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol. 1996;27:611–616
  31. Rutgers A, Heeringa P, Kooman JP, van der Sande FM, Cohen Travaert JW. Peripheral blood myeloperoxidase activity increases during hemodialysis. Kidney Int. 2003;64:760
  32. Arnhold J. Properties, functions, and secretion of human myeloperoxidase. Biochemistry. 2004;69:4–9
  33. Wang AY, Lai KN. The use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19;:1643–1652
  34. Wang AY, Lam CW, Yu CM, et al. N-Terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol. 2007;18:321–330
  35. Wang AY, Lam CW, Wang M, et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. Clin Chem. 2007;53:882–889
  36. Shabani F, McNeil J, Tippett L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCl) is suppressed by anti-rheumatic drugs. Free Radic Res. 1998;28:115–123
  37. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cyasteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001;276:41279–41287
  38. Podrez EA, Poliakov E, Shen Z, et al. A novel family of atherogenic oxidized phospholipids promotes atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem. 2002;277:38517–38523
  39. Schmitt D, Shen Z, Zhang R, et al. Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. Biochemistry. 1999;38:16904–16915
  40. McMillen TS, Heinecke JW, LeBoeuf RC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation. 2005;111:2798–2804
  41. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematol. 2000;104:10–15
  42. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604
  43. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2006;165:710–718

 Originally published online as doi:10.1053/j.ajkd.2010.05.008 on July 20, 2010.

PII: S0272-6386(10)00917-0

doi: 10.1053/j.ajkd.2010.05.008

American Journal of Kidney Diseases
Volume 56, Issue 5 , Pages 937-946 , November 2010

Article Tools

* Image Usage & Resolution